Literature DB >> 9721068

Botox-induced prostatic involution.

R Doggweiler1, D H Zermann, M Ishigooka, R A Schmidt.   

Abstract

BACKGROUND: A simple approach to induced prostatic atrophy was explored. Surgical denervation is known to produce profound atrophy of the rat prostate. Because Botulinum toxin type A (Botox) produces a long-term chemical denervation, the potential to induce atrophy of the rat prostate was explored.
METHODS: Thirty rat prostates were injected with varying doses of Botox. Single and serial injections were used, and rats were subsequently sacrificed after either 1 or 4 weeks, respectively. The prostate glands were harvested, weighed, and histologically studied for morphologic and apoptotic changes.
RESULTS: The total prostate volume and weight were found to be reduced in all Botox-injected animals. Histologically, a generalized atrophy of the glands was observed with the H&E stain. There was also diffuse glandular apoptosis evident with the Tunel stain. There were no significant complications (e.g., urinary retention, weight loss, or hind/limb weakness).
CONCLUSIONS: Botulinum toxin type A injection into the prostate gland induces selective denervation and subsequent atrophy of the prostate. Apoptosis was seen diffusely throughout the gland. It may be possible that in the future, this long-acting neurotoxin could be used for the treatment of common pathologies of the human prostate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721068     DOI: 10.1002/(sici)1097-0045(19980915)37:1<44::aid-pros7>3.0.co;2-8

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  32 in total

Review 1.  [Botulinum toxin in urology. Indications and results].

Authors:  B Schurch; A Reitz
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

Review 2.  Other therapies for BPH patients: desmopressin, anti-cholinergic, anti-inflammatory drugs, and botulinum toxin.

Authors:  Abdel-Rahmène Azzouzi; Marc Fourmarier; Francois Desgrandchamps; Charles Ballereau; Christian Saussine; Olivier Haillot; Bertrand Lukacs; Marian Devonec; Alexandre de la Taille
Journal:  World J Urol       Date:  2006-05-18       Impact factor: 4.226

3.  The use of botulinum toxin in men with benign prostatic hyperplasia.

Authors:  Susan R Rusnack; Steven A Kaplan
Journal:  Rev Urol       Date:  2005

Review 4.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

Review 5.  Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery.

Authors:  Michael B Chancellor
Journal:  Int Urol Nephrol       Date:  2009-07-02       Impact factor: 2.370

Review 6.  Tumour innervation and neurosignalling in prostate cancer.

Authors:  Brayden March; Sam Faulkner; Phillip Jobling; Allison Steigler; Alison Blatt; Jim Denham; Hubert Hondermarck
Journal:  Nat Rev Urol       Date:  2020-01-14       Impact factor: 14.432

7.  Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia.

Authors:  Dong Soo Park; Taek Woo Cho; Yong Kyu Lee; Young Tae Lee; Young Kwon Hong; Woong Ki Jang
Journal:  Yonsei Med J       Date:  2006-10-31       Impact factor: 2.759

8.  Histopathological and radiological investigations of the influence of botulinum toxin on the submandibular gland of the rat.

Authors:  Berna Uslu Coskun; Hayati Savk; Esin Derin Cicek; Tulay Basak; Muzaffer Basak; Burhan Dadas
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-02-07       Impact factor: 2.503

9.  Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.

Authors:  João Silva; Rui Pinto; Tiago Carvalho; Francisco Botelho; Pedro Silva; Rui Oliveira; Carlos Silva; Francisco Cruz; Paulo Dinis
Journal:  BMC Urol       Date:  2009-08-15       Impact factor: 2.264

10.  Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis.

Authors:  Saskia Rohrbach; Katharina Junghans; Sibylle Köhler; Rainer Laskawi
Journal:  Head Face Med       Date:  2009-10-16       Impact factor: 2.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.